Adopting real-time surveillance dashboards as a component of an enterprisewide medication safety strategy.

BACKGROUND High-alert medications are frequently responsible for adverse drug events and present significant hazards to inpatients, despite technical improvements in the way they are ordered, dispensed, and administered. METHODS A real-time surveillance application was designed and implemented to enable pharmacy review of high-alert medication orders to complement existing computerized provider order entry and integrated clinical decision support systems in a tertiary care hospital. The surveillance tool integrated real-time data from multiple clinical systems and applied logical criteria to highlight potentially high-risk scenarios. Use of the surveillance system for adult inpatients was analyzed for warfarin, heparin and enoxaparin, and aminoglycoside antibiotics. RESULTS Among 28,929 hospitalizations during the study period, patients eligible to appear on a dashboard included 2224 exposed to warfarin, 8383 to heparin or enoxaparin, and 893 to aminoglycosides. Clinical pharmacists reviewed the warfarin and aminoglycoside dashboards during 100% of the days in the study period-and the heparinlenoxaparin dashboard during 71% of the days. Displayed alert conditions ranged from common events, such as 55% of patients receiving aminoglycosides were missing a baseline creatinine, to rare events, such as 0.1% of patients exposed to heparin were given a bolus greater than 10,000 units. On the basis of interpharmacist communication and electronic medical record notes recorded within the dashboards, interventions to prevent further patient harm were frequent. CONCLUSIONS Even in an environment with sophisticated computerized provider order entry and clinical decision support systems, real-time pharmacy surveillance of high-alert medications provides an important platform for intercepting medication errors and optimizing therapy.

[1]  R S Evans,et al.  Computerized surveillance of adverse drug events in hospital patients. 1991. , 1991, Quality & safety in health care.

[2]  David W. Bates,et al.  Can surveillance systems identify and avert adverse drug events? A prospective evaluation of a commercial application. , 2008, Journal of the American Medical Informatics Association : JAMIA.

[3]  T. Brennan,et al.  The nature of adverse events in hospitalized patients. Results of the Harvard Medical Practice Study II. , 1991, The New England journal of medicine.

[4]  Peter M. Kilbridge,et al.  Research Paper: Automated Surveillance for Adverse Drug Events at a Community Hospital and an Academic Medical Center , 2006, J. Am. Medical Informatics Assoc..

[5]  David W. Bates,et al.  The costs of adverse drug events in hospitalized patients. Adverse Drug Events Prevention Study Group , 1997 .

[6]  Marc Berg,et al.  Overriding of drug safety alerts in computerized physician order entry. , 2006, Journal of the American Medical Informatics Association : JAMIA.

[7]  G A Colditz,et al.  Postmarketing surveillance and adverse drug reactions: current perspectives and future needs. , 1999, JAMA.

[8]  Allison B McCoy,et al.  A computerized provider order entry intervention for medication safety during acute kidney injury: a quality improvement report. , 2010, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[9]  R S Evans,et al.  Prevention of adverse drug events through computerized surveillance. , 1992, Proceedings. Symposium on Computer Applications in Medical Care.

[10]  Shyam Visweswaran,et al.  Assessing the Performance Characteristics of Signals Used by a Clinical Event Monitor to Detect Adverse Drug Reactions in the Nursing Home , 2008, AMIA.

[11]  L. Kohn,et al.  To Err Is Human : Building a Safer Health System , 2007 .

[12]  J. Peterson,et al.  Improving aminoglycoside dosing through computerized clinical decision support and pharmacy therapeutic monitoring systems. , 2008, AMIA ... Annual Symposium proceedings. AMIA Symposium.

[13]  Diane L. Seger,et al.  Research Paper: Impact of Non-interruptive Medication Laboratory Monitoring Alerts in Ambulatory Care , 2009, J. Am. Medical Informatics Assoc..

[14]  D. Bates,et al.  Effect of computerized physician order entry and a team intervention on prevention of serious medication errors. , 1998, JAMA.

[15]  D. Bates,et al.  The Costs of Adverse Drug Events in Hospitalized Patients , 1997 .

[16]  Joshua Borus,et al.  Adverse drug events in ambulatory care. , 2003, The New England journal of medicine.

[17]  Asif Ahmad,et al.  Implementation of a System for Computerized Adverse Drug Event Surveillance and Intervention at an Academic Medical Center , 2006 .

[18]  R. Resar,et al.  Adverse drug event trigger tool: a practical methodology for measuring medication related harm , 2003, Quality & safety in health care.

[19]  D. Wysowski,et al.  Adverse drug event surveillance and drug withdrawals in the United States, 1969-2002: the importance of reporting suspected reactions. , 2005, Archives of internal medicine.

[20]  D. Bates,et al.  Prioritizing strategies for preventing medication errors and adverse drug events in pediatric inpatients. , 2003, Pediatrics.

[21]  A. Wall,et al.  Book ReviewTo Err is Human: building a safer health system Kohn L T Corrigan J M Donaldson M S Washington DC USA: Institute of Medicine/National Academy Press ISBN 0 309 06837 1 $34.95 , 2000 .

[22]  D. Bates,et al.  Pharmacist participation on physician rounds and adverse drug events in the intensive care unit. , 1999, JAMA.

[23]  N. Laird,et al.  Incidence of Adverse Drug Events and Potential Adverse Drug Events: Implications for Prevention , 1995 .

[24]  Jacob A. McCoy,et al.  Effects of clinical decision support on initial dosing and monitoring of tobramycin and amikacin. , 2011, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.